TY - JOUR
T1 - Measuring lipoprotein(a) for cardiovascular disease prevention - in whom and when?
AU - Thomas, Peter E
AU - Vedel-Krogh, Signe
AU - Nordestgaard, Børge G
N1 - Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2024/1/1
Y1 - 2024/1/1
N2 - PURPOSE OF REVIEW: The aim of this study is to summarize major cardiovascular guideline recommendations on lipoprotein(a) and highlighting recent findings that emphasize how measuring lipoprotein(a) once in all adults is meaningful regardless of age, sex, comorbidities, or ethnicity.RECENT FINDINGS: Many international guidelines now recommend once in a lifetime measurement of lipoprotein(a) in all adult individuals to facilitate accurate risk prediction. Lipoprotein(a)-lowering therapy to reduce cardiovascular disease is on the horizon, with results from the first phase 3 trial expected in 2025.SUMMARY: Elevated lipoprotein(a) is an independent causal risk factor for atherosclerotic cardiovascular disease and aortic valve stenosis and measuring lipoprotein(a) once in all individuals regardless of age, sex, comorbidities, or ethnicity is meaningful to aid in risk stratification.
AB - PURPOSE OF REVIEW: The aim of this study is to summarize major cardiovascular guideline recommendations on lipoprotein(a) and highlighting recent findings that emphasize how measuring lipoprotein(a) once in all adults is meaningful regardless of age, sex, comorbidities, or ethnicity.RECENT FINDINGS: Many international guidelines now recommend once in a lifetime measurement of lipoprotein(a) in all adult individuals to facilitate accurate risk prediction. Lipoprotein(a)-lowering therapy to reduce cardiovascular disease is on the horizon, with results from the first phase 3 trial expected in 2025.SUMMARY: Elevated lipoprotein(a) is an independent causal risk factor for atherosclerotic cardiovascular disease and aortic valve stenosis and measuring lipoprotein(a) once in all individuals regardless of age, sex, comorbidities, or ethnicity is meaningful to aid in risk stratification.
KW - Adult
KW - Humans
KW - Lipoprotein(a)
KW - Cardiovascular Diseases/prevention & control
KW - Atherosclerosis/etiology
KW - Risk Factors
KW - Aortic Valve Stenosis
UR - http://www.scopus.com/inward/record.url?scp=85179643556&partnerID=8YFLogxK
U2 - 10.1097/HCO.0000000000001104
DO - 10.1097/HCO.0000000000001104
M3 - Review
C2 - 38078600
SN - 0268-4705
VL - 39
SP - 39
EP - 48
JO - Current Opinion in Cardiology
JF - Current Opinion in Cardiology
IS - 1
ER -